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Letters to the Editorthromboembolism. We5 also sup-
ported this strategy. ElBardissi and
colleagues1 are to be congratulated
for their elegant, albeit retrospective
institutional analysis that brings
additional light to this controversial
problem. Once again, there is a
need to revise current guidelines
that should not be taken as law.
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We appreciate the comments from
Drs Mestres and Aramendi regarding
our retrospective institutional analysis,The Journalwhich identified no difference in the
overall incidence of thromboembolic
events in patients who electively re-
ceived anticoagulants after bioprosthetic
aortic valve implantation.1 Althoughwe
identified subsets of patients that may
benefit from some form of antithrom-
botic therapy in the immediate postoper-
ative phase (either antiplatelet therapy or
a vitamin K antagonist with a goal inter-
national normalized ratio of 2 to 3), our
findings differ markedly from the
American Heart Association/American
College of Cardiology (AHA/ACC)
andother international cardiac organiza-
tions, which recommend anticoagula-
tion with a vitamin K antagonist for
the first 90 postoperative days.2
Since publication of the article by
Heras and associates3 from the Mayo
Clinic that ultimately inspired these
aggressive anticoagulation recommen-
dations, there have been a plethora of
retrospective studies suggesting that
anticoagulation is unnecessary and
may be harmful. In fact, Sundt and
colleagues4 recently updated and re-
reviewed the Mayo Clinic series and
found that anticoagulation did not
provide additional protection from
thromboembolic events. Our thorough
analysis of the outcomes from the
Brigham and Women’s Hospital dem-
onstrated that only high-risk groups
may benefit from some type of antith-
rombotic therapy. It should be noted,
however, that in these high-risk pa-
tients, the optimal form of early antith-
rombotic therapy is still up for debate.
In one of the few prospective, ran-
domized, multi-institution studies ex-
amining this important clinical
question, Aramendi and colleagues5
identified an important outcome that
has not been demonstrated in most
single-institution retrospective studies,
including ours: patients who receive
anticoagulation with a vitamin K an-
tagonist have bleeding complications
at a much higher rate than those who
are treated with a platelet inhibitor.
Although these findings may be
intuitive, they warrant recognition inas-
much as surgeons considering antith-of Thoracic and Cardiovascular Surgerombotic therapy in high-risk patients
should be cognizant of the potential
bleeding complications after treatment
with vitamin K antagonists in this spe-
cific group of patients. Further, high-
riskpatients inour analysis had a similar
reduction in thromboembolic events
irrespective of the mode of antithrom-
botic therapy (aspirin versus warfarin
sodium [Coumadin]). These compli-
mentary findings suggest that antiplate-
let therapy after bioprosthetic aortic
valve replacement may provide the
optimal balance between efficacy and
safety.
The time may have come for the
AHA/ACC to reconsider their antith-
rombotic therapy recommendations
after bioprosthetic aortic valve replace-
ment. There now exists a large amount
of data that suggest widespread antico-
agulation is not indicated, and perhaps
more concerning, patients administered
vitamin K antagonists may be at a
significant risk of major bleeding
complications.
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ASSOCIATEDWITH PEDIATRIC
AND CONGENITAL CARDIAC
SURGERY
To the Editor:
We congratulate Furck and col-
leagues1 for their excellent analysis of
outcomes after the Norwood operation
in patients with hypoplastic left heart
syndrome, as described in their recent
publication. However, we are con-
cerned that the authors have reported
the rate ofmortality using a nonstandard
strategy for this type of reporting. Furck
and colleagues reported a 30-day mor-
tality of 2.5% for the last 3 years.
They stated that ‘‘Death after this period
and until the subsequent palliative sur-
gery, regardless of whether in or out of
the hospital, was defined as interstage
mortality.’’ They reported interstage
mortality of 15%. This manner of
reporting of outcomes is not consistent
with standardized reporting strategies.
It can be potentially misleading and
can create unrealistic expectations
among referring physicians, caregivers,
and families.
Collaborative international efforts
have resulted in the establishment of
standardized methodologies for the
reporting of mortality and morbidity
associated with pediatric and congen-
ital cardiac surgery.2,3 Operative
mortality is defined as any death, re-
gardless of cause, occurring (1) within
30 days after surgical intervention in
or out of the hospital and (2) after 30
days during the same hospitalization
subsequent to the operation. Thus op-
erative mortality includes all deaths726 The Journal of Thoracic and Cthat occur during the initial hospitali-
zation. Logically, interstage mortality
encompasses all deaths that occur after
the period of time included in opera-
tive mortality but before the stage 2
operation. Thus all mortality during
the initial hospitalization should be
classified as operative mortality and
not interstage mortality.
The most recent analysis of the
Society of Thoracic Surgeons Congen-
ital Heart Surgery Database documents
discharge mortality of 18.7% (447/
2395 patients) after the Norwood (stage
I) operation.4 By reporting only 30-day
mortality and classifying deaths that oc-
cur after 30 days but during the initial
hospitalization as interstage mortality,
the authors have used a methodology
not consistent with standardized meth-
odologies of outcome reporting. If an
author wishes to explore other means
of presentation, one would assume
that it would be done with a degree of
emphasis that was not apparent in this
article. We believe that the use of stan-
dard reporting strategies for mortality is
crucial when reporting the outcomes
after pediatric and congenital cardiac
surgery.
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We thank Jonas and his colleagues
for their interest in our study and for
drawing our attention to the definition
of operative mortality.1
During the review process of the
manuscript, we offered to recalculate
our data on mortality of the Nor-
wood operation according to the def-
inition of The Society of Thoracic
Surgeons Congenital Database Task-
force and the Joint EACTS–STS
Congenital Database Committee,2
but as we gave data on both 30-day
mortality and interstage mortality,
we were allowed to leave the data
as presented.
However, we agree with Jonas and
colleagues that the way of reporting
operative mortality should be consis-
tent to simplify comparison between
groups. We, therefore, recalculated0
